Distinct CSF biomarker-associated DNA methylation in Alzheimer’s disease and cognitively normal subjects

Background Growing evidence has demonstrated that DNA methylation (DNAm) plays an important role in Alzheimer’s disease (AD) and that DNAm differences can be detected in the blood of AD subjects. Most studies have correlated blood DNAm with the clinical diagnosis of AD in living individuals. However, as the pathophysiological process of AD can begin many years before the onset of clinical symptoms, there is often disagreement between neuropathology in the brain and clinical phenotypes. Therefore, blood DNAm associated with AD neuropathology, rather than with clinical data, would provide more relevant information on AD pathogenesis. Methods We performed a comprehensive analysis to identify blood DNAm associated with cerebrospinal fluid (CSF) pathological biomarkers for AD. Our study included matched samples of whole blood DNA methylation, CSF Aβ42, phosphorylated tau181 (pTau181), and total tau (tTau) biomarkers data, measured on the same subjects and at the same clinical visits from a total of 202 subjects (123 CN or cognitively normal, 79 AD) in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. To validate our findings, we also examined the association between premortem blood DNAm and postmortem brain neuropathology measured on a group of 69 subjects in the London dataset. Results We identified a number of novel associations between blood DNAm and CSF biomarkers, demonstrating that changes in pathological processes in the CSF are reflected in the blood epigenome. Overall, the CSF biomarker-associated DNAm is relatively distinct in CN and AD subjects, highlighting the importance of analyzing omics data measured on cognitively normal subjects (which includes preclinical AD subjects) to identify diagnostic biomarkers, and considering disease stages in the development and testing of AD treatment strategies. Moreover, our analysis revealed biological processes associated with early brain impairment relevant to AD are marked by DNAm in the blood, and blood DNAm at several CpGs in the DMR on HOXA5 gene are associated with pTau181 in the CSF, as well as tau-pathology and DNAm in the brain, nominating DNAm at this locus as a promising candidate AD biomarker. Conclusions Our study provides a valuable resource for future mechanistic and biomarker studies of DNAm in AD.

[1]  I. Guénal,et al.  A High-Throughput Search for SFXN1 Physical Partners Led to the Identification of ATAD3, HSD10 and TIM50 , 2022, Biology.

[2]  Juan I. Young,et al.  Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer’s disease , 2022, Nature Communications.

[3]  J. Shim,et al.  TRIM family proteins: roles in proteostasis and neurodegenerative diseases , 2022, Open Biology.

[4]  E. Minikel,et al.  Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials , 2022, Scientific Reports.

[5]  R. Maccioni,et al.  Glucose metabolism and AD: evidence for a potential diabetes type 3 , 2022, Alzheimer's research & therapy.

[6]  S. Chen,et al.  Cross-tissue meta-analysis of blood and brain epigenome-wide association studies in Alzheimer's disease , 2022, medRxiv.

[7]  E. Fisher,et al.  RNA splicing regulators play critical roles in neurogenesis , 2022, Wiley interdisciplinary reviews. RNA.

[8]  J. Mill,et al.  DNA methylation signatures of Alzheimer’s disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types , 2022, bioRxiv.

[9]  Keith A. Johnson,et al.  Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. , 2022, JAMA neurology.

[10]  E. Haacke,et al.  Quantitative Susceptibility Mapping of Brain Iron Relating to Cognitive Impairment in Hypertension , 2022, Journal of magnetic resonance imaging : JMRI.

[11]  Gary D Bader,et al.  The reactome pathway knowledgebase 2022 , 2021, Nucleic Acids Res..

[12]  J. Weuve,et al.  Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060) , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[13]  Ryan L. Collins,et al.  Genome-wide enhancer maps link risk variants to disease genes , 2021, Nature.

[14]  R. Marioni,et al.  Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders , 2021, Genome biology.

[15]  J. Kril,et al.  Defining early changes in Alzheimer’s disease from RNA sequencing of brain regions differentially affected by pathology , 2021, Scientific Reports.

[16]  Juan I. Young,et al.  MethReg: estimating the regulatory potential of DNA methylation in gene transcription , 2021, bioRxiv.

[17]  M. Chami,et al.  Calcium Signalling in Alzheimer’s Disease: From Pathophysiological Regulation to Therapeutic Approaches , 2021, Cells.

[18]  Annelot M. Dekker,et al.  Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation , 2021, Nature Genetics.

[19]  A. Murray,et al.  DNA methylation analysis of candidate genes associated with dementia in peripheral blood. , 2020, Epigenomics.

[20]  Juan I. Young,et al.  Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer’s disease , 2020, Nature Communications.

[21]  K. Ozaki,et al.  Lower DNA methylation levels in CpG island shores of CR1, CLU, and PICALM in the blood of Japanese Alzheimer’s disease patients , 2020, PloS one.

[22]  M. Mimura,et al.  Increased blood COASY DNA methylation levels a potential biomarker for early pathology of Alzheimer’s disease , 2020, Scientific Reports.

[23]  Zina M. Ibrahim,et al.  An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene , 2020, Neurobiology of Aging.

[24]  G. Bernier,et al.  The Role of BMI1 in Late-Onset Sporadic Alzheimer’s Disease , 2020, Genes.

[25]  J. Waring,et al.  Harnessing peripheral DNA methylation differences in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease , 2020, Clinical Epigenetics.

[26]  A. Murray,et al.  Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms , 2020, Alzheimer's & dementia.

[27]  J. Trojanowski,et al.  Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays , 2019, Scientific Reports.

[28]  A. Bardet,et al.  Sensitivity of transcription factors to DNA methylation , 2019, Essays in biochemistry.

[29]  Liang-Jun Yan,et al.  Role of Catalase in Oxidative Stress- and Age-Associated Degenerative Diseases , 2019, Oxidative Medicine and Cellular Longevity.

[30]  Genetic,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[31]  P. Qiu,et al.  Correlation Patterns Between DNA Methylation and Gene Expression in The Cancer Genome Atlas , 2019, Cancer informatics.

[32]  Pei Fen Kuan,et al.  methylGSA: a Bioconductor package and Shiny app for DNA methylation data length bias adjustment in gene set testing , 2018, Bioinform..

[33]  J. Morris,et al.  Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative , 2018, Alzheimer's & Dementia.

[34]  Saurav Mallik,et al.  An evaluation of supervised methods for identifying differentially methylated regions in Illumina methylation arrays , 2018, Briefings Bioinform..

[35]  Sterling C. Johnson,et al.  DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.

[36]  K. Cheung,et al.  Calcium signaling in Alzheimer's disease & therapies. , 2018, Biochimica et biophysica acta. Molecular cell research.

[37]  F. Coppedè,et al.  Role of epigenetics in Alzheimer's disease pathogenesis. , 2018, Neurodegenerative disease management.

[38]  J. Adjaye,et al.  Modeling Late-Onset Sporadic Alzheimer's Disease through BMI1 Deficiency. , 2018, Cell reports.

[39]  Rondi A. Butler,et al.  An optimized library for reference-based deconvolution of whole-blood biospecimens assayed using the Illumina HumanMethylationEPIC BeadArray , 2018, Genome Biology.

[40]  Lei Wang,et al.  Increased Iron Deposition on Brain Quantitative Susceptibility Mapping Correlates with Decreased Cognitive Function in Alzheimer's Disease. , 2018, ACS chemical neuroscience.

[41]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[42]  D. Bennett,et al.  Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer’s disease neuropathology , 2018, Alzheimer's & Dementia.

[43]  L. Christiansen,et al.  Epigenome-Wide Association Study of Cognitive Functioning in Middle-Aged Monozygotic Twins , 2017, Front. Aging Neurosci..

[44]  D. Schübeler,et al.  Impact of cytosine methylation on DNA binding specificities of human transcription factors , 2017, Science.

[45]  Yan Zhou,et al.  Characterizing Brain Iron Deposition in Patients with Subcortical Vascular Mild Cognitive Impairment Using Quantitative Susceptibility Mapping: A Potential Biomarker , 2017, Front. Aging Neurosci..

[46]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[47]  Anil Kumar,et al.  Role of Glutathione-S-transferases in neurological problems , 2017, Expert opinion on therapeutic patents.

[48]  S. Hatakeyama,et al.  TRIM proteins and diseases. , 2017, Journal of biochemistry.

[49]  Shijie C. Zheng,et al.  A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies , 2017, bioRxiv.

[50]  A. Hofman,et al.  Disease variants alter transcription factor levels and methylation of their binding sites , 2016, Nature Genetics.

[51]  C. Hetz,et al.  Glucose Metabolism: A Sweet Relief of Alzheimer’s Disease , 2016, Current Biology.

[52]  J. Lucas,et al.  Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome , 2016, Brain pathology.

[53]  D. Bennett,et al.  The epigenome in Alzheimer’s disease: current state and approaches for a new path to gene discovery and understanding disease mechanism , 2016, Acta Neuropathologica.

[54]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[55]  Jiang Qian,et al.  Transcription factors as readers and effectors of DNA methylation , 2016, Nature Reviews Genetics.

[56]  P. Eline Slagboom,et al.  Controlling bias and inflation in epigenome- and transcriptome-wide association studies using the empirical null distribution , 2016, bioRxiv.

[57]  J. Mill,et al.  Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes , 2015, Epigenetics.

[58]  Wei Chen,et al.  A systematic study of normalization methods for Infinium 450K methylation data using whole-genome bisulfite sequencing data , 2015, Epigenetics.

[59]  Karen M Rodrigue,et al.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.

[60]  Manolis Kellis,et al.  Alzheimer’s loci: epigenetic associations and interaction with genetic factors , 2015, Annals of clinical and translational neurology.

[61]  A. Primavera,et al.  Glutathione transferases and neurodegenerative diseases , 2015, Neurochemistry International.

[62]  Carlos Cruchaga,et al.  The epigenetic landscape of Alzheimer's disease , 2014, Nature Neuroscience.

[63]  Manolis Kellis,et al.  Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci , 2014 .

[64]  C. Ballantyne,et al.  High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. , 2014, European heart journal.

[65]  M. Endres,et al.  The heart of the matter: a link between troponin and dementia? , 2014, European heart journal.

[66]  K. Bahar Halpern,et al.  Paradoxical Role of DNA Methylation in Activation of FoxA2 Gene Expression during Endoderm Development* , 2014, The Journal of Biological Chemistry.

[67]  John D. Blischak,et al.  Methylation QTLs Are Associated with Coordinated Changes in Transcription Factor Binding, Histone Modifications, and Gene Expression Levels , 2014, bioRxiv.

[68]  J. Qian,et al.  DNA methylation presents distinct binding sites for human transcription factors , 2013, eLife.

[69]  Jack Waters,et al.  Altered Calcium Metabolism in Aging CA1 Hippocampal Pyramidal Neurons , 2013, The Journal of Neuroscience.

[70]  R. Weksberg,et al.  Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray , 2013, Epigenetics.

[71]  Francesco Marabita,et al.  A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data , 2012, Bioinform..

[72]  Paco Martorell,et al.  Monetary costs of dementia in the United States. , 2013, The New England journal of medicine.

[73]  Brent S. Pedersen,et al.  Comb-p: software for combining, analyzing, grouping and correcting spatially correlated P-values , 2012, Bioinform..

[74]  A. Wyrobek,et al.  Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases , 2012, Current genomics.

[75]  V. Fuster,et al.  The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease , 2012, Annals of the New York Academy of Sciences.

[76]  R. Sahathevan,et al.  Dementia, Stroke, and Vascular Risk Factors; a Review , 2012, International journal of stroke : official journal of the International Stroke Society.

[77]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[78]  G. Ricevuti,et al.  Linking atherosclerosis to Alzheimer's disease: focus on biomarkers. , 2012, Frontiers in bioscience.

[79]  Clifford R Jack,et al.  Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.

[80]  P. Penzes,et al.  Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease , 2011, Brain Research Reviews.

[81]  Jerry Yang,et al.  Inhibitors of Catalase-Amyloid Interactions Protect Cells from β-Amyloid-Induced Oxidative Stress and Toxicity* , 2010, The Journal of Biological Chemistry.

[82]  I. Benseñor,et al.  Subclinical hyperthyroidism and dementia: the Sao Paulo Ageing & Health Study (SPAH) , 2010, BMC public health.

[83]  Cory Y. McLean,et al.  GREAT improves functional interpretation of cis-regulatory regions , 2010, Nature Biotechnology.

[84]  A. Andreadis,et al.  Heterogeneous nuclear ribonucleoprotein E3 modestly activates splicing of tau exon 10 via its proximal downstream intron, a hotspot for frontotemporal dementia mutations. , 2010, Gene.

[85]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[86]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[87]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[88]  Robert E. Blair,et al.  Aging is associated with elevated intracellular calcium levels and altered calcium homeostatic mechanisms in hippocampal neurons , 2007, Neuroscience Letters.

[89]  S. Krieger,et al.  Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells , 2007, BMC Molecular Biology.

[90]  Huan Yang,et al.  Activation of a Methylated Promoter Mediated by a Sequence-specific DNA-binding Protein, RFX* , 2005, Journal of Biological Chemistry.

[91]  W. Markesbery,et al.  Ribosome Dysfunction Is an Early Event in Alzheimer's Disease , 2005, The Journal of Neuroscience.

[92]  A. Smith,et al.  Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease , 2004, Neurology.

[93]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[94]  D. Selkoe Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[95]  A Hofman,et al.  Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study , 2000, Clinical endocrinology.

[96]  K. Roeder,et al.  Genomic Control for Association Studies , 1999, Biometrics.

[97]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[98]  Sunil Mukherjee,et al.  Enhancer-origin interaction in plasmid R6K involves a DNA loop mediated by initiator protein , 1988, Cell.

[99]  D. Mann,et al.  A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease , 1987, Journal of the Neurological Sciences.